Immunoreactive low-molecular-weight epidermal growth factor in urine of patients with renal cell carcinoma

Urol Res. 1992;20(4):293-6. doi: 10.1007/BF00300262.

Abstract

A specific heterogeneous enzyme-linked immunosorbent assay (ELISA) has been established in order to determine levels of low-molecular-weight epidermal growth factor (EGF) in the urine of patients with renal cell carcinoma who had undergone unilateral radical nephrectomy. Urine specimens, i.e., 20 pre- and postsurgical specimens from a group of patients and 22 from a control group, were assayed after the urine had been freed from high-molecular-weight proteins (greater than 30 kDa) and salts. EGF levels were expressed as urinary EGF/creatinine ratios, and a highly significant decrease (alpha = 0.0005 by Student's t-test) of urinary EGF was found in the patient group prior to surgery. The cancer patients also showed an additional loss of urinary EGF after unilateral nephrectomy (alpha = 0.0005 by Student's t-test). These data correlate with our previous findings that pro-EGF gene expression is decreased in human renal carcinoma and support the concept that low-molecular-weight urinary EGF is derived from high-molecular-weight kidney pro-EGF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / urine*
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / urine*
  • Enzyme-Linked Immunosorbent Assay
  • Epidermal Growth Factor / genetics
  • Epidermal Growth Factor / urine*
  • Female
  • Gene Expression / genetics
  • Humans
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / urine*
  • Male
  • Middle Aged

Substances

  • Biomarkers, Tumor
  • Epidermal Growth Factor